Mesoblast Advances U.S. Launch of Ryoncil® with $160M Boost and Pipeline Milestones

• Ryoncil® commercial launch planned in the U.S. this quarter targeting pediatric SR-aGvHD
• Successful $160 million financing increases cash reserves to approximately $200 million
• Robust late-stage pipeline includes Revascor® for heart failure and Rexlemestrocel-L for chronic low back pain
• Strategic commercial leadership team and logistics partnerships established for launch